tumor sequencing
Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients
Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.
Illumina, Allegheny Health Network Collaborate on Study of Cancer Genomic Profiling
They'll assess the value of in-house testing and see if blood samples provide additional information to solid samples that could be used in therapy selection.
NGeneBio Receives CE-IVD Mark for NGS-Based Cancer Panel
The firm's accompanying software analyzes companion diagnostic biomarkers such as EGFR, BRAF, KRAS, HER2, and ROS1 genes.
The genetic testing and health intelligence firm will start trading on the Nasdaq Global Select Market on Friday under the ticker symbols SMFR and SMFRW.
Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year
Premium
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
Feb 5, 2021
Feb 29, 2020
NantHealth Q4 Revenues Grow 6 Percent
Nov 19, 2019
Nov 12, 2019
FDA Clears NantHealth Tumor-Normal Whole-Exome Test
Nov 7, 2019
NantHealth Q3 Revenues Increase Marginally
Aug 8, 2019
NantHealth Q2 Revenues Grow 17 Percent
May 9, 2019
NantHealth Q1 Revenues Increase 6 Percent
Mar 28, 2019
NantHealth Q4 Revenues Increase 3 Percent
Sep 27, 2018